PHARMACEUTICAL TECHNOLOGY INDEX 1984

AUTHORS

Adair, F.W. See Chapman, K.G.

Akers, Michael J. Considerations in selecting antimicrobial preservative agents for parenteral product development. May 1984, p. 36.

Alegnani, W.C. See Chapman, K.G.

Amos, R.L. See Chapman, K.G.

Amsel, L.P.; Hinsvark, O.N.; Rotenberg, K.; and Sheumaker, J.L. Recent advances in sustained-release technology using ion-exchange polymers. April 1984, p. 28.

Baker, R.W.; Tuttle, M.E.; and Helwing, R. Novel erodible polymers for the delivery of macromolecules. Feb. 1984, p. 26.

Brady, Edward S. A fresh look at new dosage forms. Aug. 1984, p. 22.

Bugbee, Thomas. Fueling the biotechnology fire. April 1984, p. 16.

Campbell, R.J. See Yoakam, D.A.

Cardner, Robert Y. GMP compliance auditing. Sept. 1984, p. 114.

Chafetz, Lester. Bulk drug substances and purity: an industry viewpoint. Oct. 1984, p. 24.

Chambliss, Walter G. The characterization of raw materials. June 1984, p. 83.

Chapman, K.G. The PAR approach to process validation. Dec. 1984, p. 22.

Chapman, K.G.; Alegnani, W.C.; Heinze, G.E.; Flemming, C.V.; Kochling, J.; Croll, D.B.; Fitch, M.W.; Kladko, M.; Lehman, W.J.; Smith, D.C.; Adair, F.W.; Amos, R.L.; Enzinger, R.M.; Frieben, W.R.; and Soli, T.C. Protection of water treatment systems, part III: validation and control. Sept. 1984, p. 54.

Chen, A.C. See Rizzuto, A.B.

Christian, Robert R. See Goshko, Marc A.

Cooper, Dale E. Problems in bulk pharmaceutical chemical production: an FDA investigator's view. June 1984, p. 72.

Cowsar, D.R. See Tice, T.R.

Cox, Don C.; Furman, William B.; Moore, Terry W.; and Wells, Clyde E. Guidelines for dissolution testing: an addendum. Feb. 1984, p. 42.

Croll, D.B. See Chapman, K.G.

Dao, Thi D. The future of R&D. June 1984, p. 16.

Dickinson, James. Washington report. Monthly column. Jan. 1984–Dec. 1984.

Dodge, F.J. Digital computer control of batch sterilization. June 1984, p. 60.

DuRoss, James W. Modification of the crystalline structure of sorbitol and its effects on tableting characteristics. Sept. 1984, p. 42.

Dwyer, J.; Findeisen, C.; and Skea, W. Chromatographic purification of beta-lactam antibiotics. Sept. 1984, p. 100.

Enzinger, R.M. See Chapman, K.G

Findeisen, C. See Dwyer, J.

Fitch, M.W. See Chapman, K.G.

Fleischhauer, H. The cost of GLP compliance. Jan. 1984, p. 26.

Flemming, C.V. See Chapman K.G.

Forbes, St. John. See Mathur, Leo K.

Forster, Howard, and Steve, Edward H. Predicting variable refrigeration and steam demands in batch-type bulk pharmaceutical plants, part II: step-wide plant-wide refrigeration and steam demands. May 1984, p. 24.

Fraade, D.J. An overview of applying process computer systems to sterile operations. May 1984, p. 48.

Frieben, W.R. See Chapman, K.G.

Froment, P.J.M. See Lhoest, W.J.F.

Fry, Edmund M. An FDA perspective on bulk pharmaceutical chemicals. Feb. 1984, p. 48.

Furman, William B. See Cox, Don C.

Fusari, Salvatori A., and Hostetler, Gordon L. Reference thermal exposures and performance of room temperature stability studies. Jan. 1984, p. 48.

Goodhart, F.W.; Harris, M.R.; Murthy, K.S.; and Nesbitt, R.U. An evaluation of aqueous film-forming dispersions for controlled release. April 1984, p. 64.

Goshko, M.A. The use of TTC in USP plate count medium for enumerating low levels of bacteria from insoluble materials. Nov. 1984, p. 58.

Goshko, Marc A.; Pipes, Wesley O.; and Christian, Robert R. Possible confusion between *Enterobacter agglomerans* and *Escherichia coli*. Feb. 1984, p. 32.

Guerra, Johnny. The practical application of CGMPs to gas and high-performance liquid chromatographic systems. March 1984, p. 81.

Hakimipour, Fred. Penicillin decontamination procedures for a pharmaceutical manufacturing facility. June 1984, p. 88.

Harder, S.W. The validation of cleaning procedures. May 1984, p. 29.

Harris, M.R. See Goodhart, F.W.

Heinze, G.E. See Chapman, K.G.

Held, Joe R. Defending animal use in biomedical research. Oct. 1984, p. 16.

Helwing, R. See Baker, R.W.

Herzfeldt, C.D. Automated dissolution testing of indomethacin capsules and tablets. Sept. 1984, p. 70.

Hinsvark, O.N. See Amsel, L.P.

Hostetler, Gordon L. See Fusari, Salvatori A.

Hubert, Barbara B. Drug delivery systems: a survey of current research settings. Aug. 1984, p. 32.

Johnson, C.A. Bulk drug substances and purity: a European viewpoint. Oct. 1984, p. 28.

Kanig, Joseph L., and Rudnic, Edward M. The mechanisms of disintegrant action. April 1984, p. 50.

Kemp, M.M. See Lepore, P.D.

Kladko, M. See Chapman, K.G.

Knowles, Mark R. America's youth and the image of the pharmaceutical industry. Dec. 1984, p. 14.

Kochling, J. See Chapman, K.G.

PHARMACEUTICAL TECHNOLOGY INDEX 1984

AUTHORS

Adair, F.W. See Chapman, K.G.

Akers, Michael J. Considerations in selecting antimicrobial preservative agents for parenteral product development. May 1984, p. 36.

Alegnani, W.C. See Chapman, K.G.

Amos, R.L. See Chapman, K.G.

Amsel, L.P.; Hinsvark, O.N.; Rotenberg, K.; and Sheumaker, J.L. Recent advances in sustained-release technology using ion-exchange polymers. April 1984, p. 28.

Baker, R.W.; Tuttle, M.E.; and Helwing, R. Novel erodible polymers for the delivery of macromolecules. Feb. 1984, p. 26.

Brady, Edward S. A fresh look at new dosage forms. Aug. 1984, p. 22.

Bugbee, Thomas. Fueling the biotechnology fire. April 1984, p. 16.

Campbell, R.J. See Yoakam, D.A.

Cardner, Robert Y. GMP compliance auditing. Sept. 1984, p. 114.

Chafetz, Lester. Bulk drug substances and purity: an industry viewpoint. Oct. 1984, p. 24.

Chambliss, Walter G. The characterization of raw materials. June 1984, p. 83.

Chapman, K.G. The PAR approach to process validation. Dec. 1984, p. 22.

Chapman, K.G.; Alegnani, W.C.; Heinze, G.E.; Flemming, C.V.; Kochling, J.; Croll, D.B.; Fitch, M.W.; Kladko, M.; Lehman, W.J.; Smith, D.C.; Adair, F.W.; Amos, R.L.; Enzinger, R.M.; Frieben, W.R.; and Soli, T.C. Protection of water treatment systems, part III: validation and control. Sept. 1984, p. 54.

Chen, A.C. See Rizzuto, A.B.

Christian, Robert R. See Goshko, Marc A.

Cooper, Dale E. Problems in bulk pharmaceutical chemical production: an FDA investigator's view. June 1984, p. 72.

Cowsar, D.R. See Tice, T.R.

Cox, Don C.; Furman, William B.; Moore, Terry W.; and Wells, Clyde E. Guidelines for dissolution testing: an addendum. Feb. 1984, p. 42.

Croll, D.B. See Chapman, K.G.

Dao, Thi D. The future of R&D. June 1984, p. 16.

Dickinson, James. Washington report. Monthly column. Jan. 1984–Dec. 1984.

Dodge, F.J. Digital computer control of batch sterilization. June 1984, p. 60.

DuRoss, James W. Modification of the crystalline structure of sorbitol and its effects on tableting characteristics. Sept. 1984, p. 42.

Dwyer, J.; Findeisen, C.; and Skea, W. Chromatographic purification of beta-lactam antibiotics. Sept. 1984, p. 100.

Enzinger, R.M. See Chapman, K.G

Findeisen, C. See Dwyer, J.

Fitch, M.W. See Chapman, K.G.

Fleischhauer, H. The cost of GLP compliance. Jan. 1984, p. 26.

Flemming, C.V. See Chapman K.G.

Forbes, St. John. See Mathur, Leo K.

Forster, Howard, and Steve, Edward H. Predicting variable refrigeration and steam demands in batch-type bulk pharmaceutical plants, part II: step-wide plant-wide refrigeration and steam demands. May 1984, p. 24.

Fraade, D.J. An overview of applying process computer systems to sterile operations. May 1984, p. 48.

Frieben, W.R. See Chapman, K.G.

Froment, P.J.M. See Lhoest, W.J.F.

Fry, Edmund M. An FDA perspective on bulk pharmaceutical chemicals. Feb. 1984, p. 48.

Furman, William B. See Cox, Don C.

Fusari, Salvatori A., and Hostetler, Gordon L. Reference thermal exposures and performance of room temperature stability studies. Jan. 1984, p. 48.

Goodhart, F.W.; Harris, M.R.; Murthy, K.S.; and Nesbitt, R.U. An evaluation of aqueous film-forming dispersions for controlled release. April 1984, p. 64.

Goshko, M.A. The use of TTC in USP plate count medium for enumerating low levels of bacteria from insoluble materials. Nov. 1984, p. 58.

Goshko, Marc A.; Pipes, Wesley O.; and Christian, Robert R. Possible confusion between *Enterobacter agglomerans* and *Escherichia coli*. Feb. 1984, p. 32.

Guerra, Johnny. The practical application of CGMPs to gas and high-performance liquid chromatographic systems. March 1984, p. 81.

Hakimipour, Fred. Penicillin decontamination procedures for a pharmaceutical manufacturing facility. June 1984, p. 88.

Harder, S.W. The validation of cleaning procedures. May 1984, p. 29.

Harris, M.R. See Goodhart, F.W.

Heinze, G.E. See Chapman, K.G.

Held, Joe R. Defending animal use in biomedical research. Oct. 1984, p. 16.

Helwing, R. See Baker, R.W.

Herzfeldt, C.D. Automated dissolution testing of indomethacin capsules and tablets. Sept. 1984, p. 70.

Hinsvark, O.N. See Amsel, L.P.

Hostetler, Gordon L. See Fusari, Salvatori A.

Hubert, Barbara B. Drug delivery systems: a survey of current research settings. Aug. 1984, p. 32.

Johnson, C.A. Bulk drug substances and purity: a European viewpoint. Oct. 1984, p. 28.

Kanig, Joseph L., and Rudnic, Edward M. The mechanisms of disintegrant action. April 1984, p. 50.

Kemp, M.M. See Lepore, P.D.

Kladko, M. See Chapman, K.G.

Knowles, Mark R. America's youth and the image of the pharmaceutical industry. Dec. 1984, p. 14.

Kochling, J. See Chapman, K.G.

Lehman, W.J. See Chapman, K.G.
Lepore, P.D. and Kemp, M.M. FDA's GLP regulations: proposals for change. Jan. 1984, p. 30.
Lhoest, W.J.F., and Froment, P.J.M. A new design for pharmaceutical facilities: the Lhoest-Froment concept. June 1984, p. 28.
Mathur, Leo K.; Forbes, St. John; and Yelvigi, Mukund. Characterization techniques for the aqueous film coating process. Oct. 1984, p. 42.
Mikkelson, Thomas J. Ophthalmic drug delivery. Sept. 1984, p. 90.
Millstein, Lloyd G. What price drug advertising? Nov. 1984, p. 16.
Moore, Terry W. See Cox, Don C.
Motise, Paul J. Validation of computerized systems in the control of drug processes: an FDA perspective. March 1984, p. 40.
Mullen, R.T. Promises and pitfalls: the realities of automation. Sept. 1984, p. 24.
Murthy, K.S. See Goodhart, F.W.
Nesbitt, R.U. See Goodhart, F.W.
Novitch, Mark. Balancing science and sense. Jan. 1984, p. 18.
Parcells, Alan J. Protein purification: past, present, and future. Sept. 1984, p. 78.
Pipes, Wesley O. See Goshko, Marc A.
PMA's Joint QC-PDS Stability Committee. Stability concepts. June 1984, p. 42.
Reeves-Ellington, Richard H. The need for product innovation. Feb. 1984, p. 18.
Rizzuto, A.B.; Chen, A.C.; and Veiga, M.F. Modification of the sucrose crystal structure to enhance pharmaceutical properties of excipient and drug substances. Sept. 1984, p. 32.
Rosencranz, Robert. Automation of HVAC and process controls in a new pharmaceutical manufacturing facility. Aug. 1984, p. 24.
Ross, Niles. FDA inspections: the limits of authority. March 1984, p. 58.
Rotenberg, K. See Amsel, L.P.
Rudnic, Edward M. See Kanig, Joseph L.
Russo, Emanuel J. Typical scale-up problems and experiences. Nov. 1984, p. 46.
Schwind, Paul. Digital control in the pharmaceutical industry: a supplier's view. June 1984, p. 50.
Sheumaker, J.L. See Amsel, L.P.
Shulman, Robert. Generic drugs: an idea whose time has come. May 1984, p. 16.
Skea, W. See Dwyer, J.
Smith, D.C. See Chapman, K.G.
Soli, T.C. See Chapman, K.G.
Steinberg, George M. Drug needs of the elderly. Aug. 1984, p. 14.
Steve, Edward H. See Forster, Howard.
Stiel, D.M. See Williams, J.J.
Stupp, Hermann. Electronic control systems for fault elimination in printed packaging. Dec. 1984, p. 38.
Tetzlaff, Ronald F. Regulatory aspects of aseptic processing. Nov. 1984, p. 38.
Thompson, Robert G. The design, documentation, and construction of pharmaceutical facilities, part I: design. Feb. 1984, p. 56.
Thompson, Robert G. The design, documentation, and construction of pharmaceutical facilities, part II: documentation. March 1984, p. 72.
Thompson, Robert G. The design, documentation, and construction of pharmaceutical facilities, part III: construction. April 1984, p. 72.
Tice, T.R., and Cowsar, D.R. Biodegradable controlled-release parenteral systems. Nov. 1984, p. 26.
Tuttle, M.E. See Baker, R.W.
Veiga, M.F. See Rizzuto, A.B.
Weiss, L. Stephen. The Chinese connection. March 1984, p. 20.
Wells, Clyde E. See Cox, Don C.
Williams, J.J., and Stiel, D.M. An intelligent tablet press monitor for formulation development. March 1984, p. 26.
Wolters, R.J. Bulk drug substances and purity: a regulatory viewpoint. Oct. 1984, p. 35.
Yelvigi, Mukund. Principles of process automation for liquid and solid dosage forms. March 1984, p. 47.
Yelvigi, Mukund. See Mathur, Leo K.
Yoakam, D.A., and Campbell, R.J. Modeling of a film coating system for computer automation. Jan. 1984, p. 38.

SUBJECTS

ABBREVIATED NDAs (see NDAs)

ABSORPTION AND ADSORPTION

The mechanisms of disintegrant action. Joseph L. Kanig and Edward M. Rudnic. April 1984, p. 50.
Ophthalmic drug delivery. Thomas J. Mikkelson. Sept. 1984, p. 90.

ADVERTISING (see also DRUG MARKETS AND MARKETING)

"Consumer Rx advertising," in Washington report. James Dickinson. Aug. 1984, p. 16.
What price drug advertising? Lloyd G. Millstein. Nov. 1984, p. 16.

AMERICAN PHARMACEUTICAL ASSOCIATION (APhA)

America's youth and the image of the pharmaceutical industry. Mark Knowles. Dec. 1984, p. 14.
"APhA changes," in Washington report. James Dickinson. April 1984, p. 20.
"APhA's new leader — and era," in Washington report. James Dickinson. Aug. 1984, p. 16.
"Apple: the last of a breed," in Washington report. James Dickinson. March 1984, p. 22.

ANIMAL TESTING

Defending animal use in biomedical research. Joe R. Held. Oct. 1984, p. 16.

ANTIBIOTICS

Chromatographic purification of beta-lactam antibiotics. J. Dwyer, C. Findeisen, and W. Skea. Sept. 1984, p. 100.
Penicillin decontamination procedures for a pharmaceutical manufacturing facility. Fred Hakimipour. June 1984, p. 88.

ASSAY AND BIOASSAY METHODS

Automated dissolution testing of indomethacin capsules and tablets. C.D. Herzfeldt. Sept. 1984, p. 70.
Possible confusion between *Enterobacter agglomerans* and *Escherichia coli*. Marc A. Goshko, Wesley O. Pipes, and Robert R. Christian. Feb. 1984, p. 32.
The use of TTC in USP plate count medium for enumerating low levels of bacteria from insoluble materials. M.A. Goshko. Nov. 1984, p. 58.
The validation of cleaning procedures. S.W. Harder. May 1984, p. 29.

AUDITS

GMP compliance auditing. Robert Y. Cardner. Sept. 1984, p. 114.
The PAR approach to process validation. K.G. Chapman. Dec. 1984, p. 22.

AUTOMATION

Automation of HVAC and process controls in a new pharmaceutical manufacturing facility. Robert Rosencranz. Aug. 1984, p. 24.
Digital computer control of batch sterilization. F.J. Dodge. June 1984, p. 60.
Digital control in the pharmaceutical industry: a supplier's view. Paul Schwind. June 1984, p. 50.
Electronic control systems for fault elimination in printed packaging. Hermann Stupp. Dec. 1984, p. 38.
An intelligent tablet press monitor for formulation development. J.J. Williams and D.M. Stiel. March 1984, p. 26.
Modeling of a film coating system for computer automation. D.A. Yoakam and R.J. Campbell. Jan. 1984, p. 38.
A new design for pharmaceutical facilities: the Lhoest-Froment concept. W.J.F. Lhoest and P.J.M. Froment. June 1984, p. 28.

An overview of applying process computer systems to sterile operations. D.J. Fraade. May 1984, p. 48.
The PAR approach to process validation. K.G. Chapman. Dec. 1984, p. 22.
The practical application of CGMPs to gas and high-performance liquid chromatographic systems. Johnny Guerra. March 1984, p. 81.
Principles of process automation for liquid and solid dosage forms. Mukund Yelvigi. March 1984, p. 47.
Promises and pitfalls: the realities of automation. R.T. Mullen. Sept. 1984, p. 24.
Validation of computerized systems in the control of drug processes: an FDA perspective. Paul J. Motise. March 1984, p. 40.

BACTERIOLOGY

Protection of water treatment systems, part III: validation and control. K.G. Chapman, W.C. Alegnani, G.E. Heinze, C.V. Flemming, J. Kochling, D.B. Croll, M.W. Fitch, M. Kladko, W.J. Lehman, D.C. Smith, F.W. Adair, R.L. Amos, R.M. Enzinger, W.R. Frieben, and T.C. Soli. Sept. 1984, p. 54.

BIOAVAILABILITY

Biodegradable controlled-release parenteral systems. T.R. Tice and D.R. Cowsar. Nov. 1984, p. 26.
Novel erodible polymers for the delivery of macromolecules. R.W. Baker, M.E. Tuttle, and R. Helwing. Feb. 1984, p. 26.
Recent advances in sustained-release technology using ion-exchange polymers. L.P. Amsel, O.N. Hinsvark, K. Rotenberg, and J.L. Sheumaker. April 1984, p. 28.

BIOTECHNOLOGY

Balancing science and sense. Mark Novitch. Jan. 1984, p. 18.
Fueling the biotechnology fire. Thomas Bugbee. April 1984, p. 16.
Protein purification: past, present, and future. Alan J. Parcells. Sept. 1984, p. 78.

BOOK REVIEWS

Attwood, D., and Florence, A.T., *Surfactant Systems: Their Chemistry, Pharmacy, and Biology*; reviewed by Michael J. Groves, Oct. 1984, p. 62.
Barry, Brian W., *Dermatological Formulations: Percutaneous Absorption*; reviewed by Michael J. Groves, Feb. 1984, p. 65.
Cadwallader, Donald E., *Biopharmaceutics and Drug Interactions*; reviewed by James Swarbrick, Feb. 1984, p. 69.
Dahneke, Barton E., ed., *Measurement of Suspended Particles by Quasi-Elastic Light Scattering*; reviewed by Michael J. Groves, Sept. 1984, p. 128.
Deasey, Patrick B., *Microencapsulation and Related Drug Processes*; reviewed by Sunil Jambhekar, Sept. 1984, p. 126.
Franks, Felix, *Water*; reviewed by Michael J. Groves, Feb. 1984, p. 64.
Goldberg, Eugene P., ed., *Targeted Drugs*; reviewed by Michael J. Groves, Oct. 1984, p. 64.
Gross, Franz, ed., *Decision Making in Drug Research*; reviewed by Jurg A. Schneider, March 1984, p. 89.
Knight, C.G., ed., *Liposomes: From Physical Structure to Therapeutic Applications*; reviewed by Michael J. Groves, March 1984, p. 90.
Melrose, Dianna, *Bitter Pills: Medicines and the Third World Poor*; reviewed by Michael J. Groves, Feb. 1984, p. 64.
Oldshue, James Y., *Fluid Mixing Technology*; reviewed by Michael J. Groves, March 1984, p. 88.
Ostro, Marc J., ed., *Liposomes*; reviewed by Michael J. Groves, March 1984, p. 90.
Stanley-Wood, Nayland, ed., *Enlargement and Compaction of Particulate Solids*; reviewed by Michael J. Groves, March 1984, p. 88.
Torrey, S., ed., *Enzyme Technology: Preparation, Purification, Stabili-*

We fill your needs from



When you choose Kodak, you can start small and finish big. Because we can deliver custom synthesis or specialty chemicals in amounts from test tubes to tank-car lots—whatever fits your needs.

With us, there are no time-consuming, "stop, gear-up, start-over" interruptions caused by switching vendors. No costly supply-run-dry situations.

For small to medium batch lots, Kodak Laboratory and Specialty Chemicals, in Rochester, is your source. When needs reach still larger volumes, Eastman Chemical Division in Kingsport, Tennessee, delivers.

There's more. We offer full-service, state-of-the-art analytical facilities. Fast answers to questions. And a staff of

zation, Immobilization, Recent Advances; reviewed by Michael J. Groves, Sept. 1984, p. 127.
U.S. Department of Health and Human Services, *Approved Prescription Drug Products with Therapeutic Equivalence Evaluations*, 4th ed.; reviewed by Edward S. Brady, April 1984, p. 84.
Willig, Sidney H., Tuckerman, Murray M., and Hitchings, William S., IV, *Good Manufacturing Practices for Pharmaceuticals: A Plan for Total Quality Control*, 2nd ed.; reviewed by C. Michael Reimringer, Jan. 1984, p. 82.

BULK PHARMACEUTICAL CHEMICALS

Bulk drug substances and purity: a European viewpoint. C.A. Johnson. Oct. 1984, p. 28.
Bulk drug substances and purity: a regulatory viewpoint. R.J. Wolters. Oct. 1984, p. 35.
Bulk drug substances and purity: an industry viewpoint. Lester Chafetz. Oct. 1984, p. 24.
The characterization of raw materials. Walter G. Chambliss. June 1984, p. 83.
The Chinese connection. L. Stephen Weiss. March 1984, p. 20.
An FDA perspective on bulk pharmaceutical chemicals. Edmund M. Fry. Feb. 1984, p. 48.
Typical scale-up problems and experiences. Emanuel J. Russo. Nov. 1984, p. 46.
The use of TTC in USP plate count medium for enumerating low levels of bacteria from insoluble materials. M.A. Goshko. Nov. 1984, p. 58.

CAPSULES

Automated dissolution testing of indomethacin capsules and tablets. C.D. Herzfeldt. Sept. 1984, p. 70.
Principles of process automation for liquid and solid dosage forms. Mukund Yelvigi. March 1984, p. 47.

CHEMICAL REACTIONS

The mechanisms of disintegrant action. Joseph L. Kanig and Edward M. Rudnic. April 1984, p. 50.

CHROMATOGRAPHY

Bulk drug substances and purity: a regulatory viewpoint. R.J. Wolters. Oct. 1984, p. 35.
Chromatographic purification of beta-lactam antibiotics. J. Dwyer, C. Findeisen, and W. Skea. Sept. 1984, p. 100.
The practical application of CGMPs to gas and high-performance liquid chromatographic systems. Johnny Guerra. March 1984, p. 81.
Protein purification: past, present, and future. Alan J. Parcells. Sept. 1984, p. 78.

CLEANING

Penicillin decontamination procedures for a pharmaceutical manufacturing facility. Fred Hakimipour. June 1984, p. 88.
The validation of cleaning procedures. S.W. Harder. May 1984, p. 29.

COATINGS

Characterization techniques for the aqueous film coating process. Leo K. Mathur, St. John Forbes, and Mukund Yelvigi. Oct. 1984, p. 42.
An evaluation of aqueous film-forming dispersions for controlled release. F.W. Goodhart, M.R. Harris, K.S. Murthy, and R.U. Nesbitt. April 1984, p. 64.
Modeling of a film coating system for computer automation. D.A. Yoakam and R.J. Campbell. Jan. 1984, p. 38.

COMPRESSION

An intelligent tablet press monitor for formulation development. J.J. Williams and D.M. Stiel. March 1984, p. 26.

test tubes to tank cars.



experienced development chemists to work with you from start to finish. Plus the ability to batch-produce any of the thousands of compounds listed in our computer files.

Look into our capabilities. Begin by sending for our "Creative Source" brochure–free. Write to Eastman Kodak Company, Kodak Laboratory and Specialty Chemicals, Department 742-B, Rochester, New York 14650. Or, to inquire directly, phone us at (716) 722-2915.

KODAK LABORATORY AND SPECIALTY CHEMICALS
The creative source.

© Eastman Kodak Company, 1983

Circle Reader Service Card No. 27

Modification of the crystalline structure of sorbitol and its effects on tableting characteristics. James W. DuRoss. Sept. 1984, p. 42.
Modification of the sucrose crystal structure to enhance pharmaceutical properties of excipient and drug substances. A.B. Rizzuto, A.C. Chen, and M.F. Veiga. Sept. 1984, p. 32.

COMPUTERS (see AUTOMATION)

CONTAMINATION (see also STERILIZATION)

Considerations in selecting antimicrobial preservative agents for parenteral product development. Michael J. Akers. May 1984, p. 36.
Penicillin decontamination procedures for a pharmaceutical manufacturing facility. Fred Hakimipour. June 1984, p. 88.
Problems in bulk pharmaceutical chemical production: an FDA investigator's view. Dale E. Cooper. June 1984, p. 72.
Protection of water treatment systems, part III: validation and control. K.G. Chapman, W.C. Alegnani, G.E. Heinze, C.V. Flemming, J. Kochling, D.B. Croll, M.W. Fitch, M. Kladko, W.J. Lehman, D.C. Smith, F.W. Adair, R.L. Amos, R.M. Enzinger, W.R. Frieben, and T.C. Soli. Sept. 1984, p. 54.
Regulatory aspects of aseptic processing. Ronald F. Tetzlaff. Nov. 1984, p. 38.

CONTROLLED RELEASE (see also DRUG DELIVERY SYSTEMS)

Biodegradable controlled-release parenteral systems. T.R. Tice and D.R. Cowsar. Nov. 1984, p. 26.
An evaluation of aqueous film-forming dispersions for controlled release. F.W. Goodhart, M.R. Harris, K.S. Murthy, and R.U. Nesbitt. April 1984, p. 64.
The mechanisms of disintegrant action. Joseph L. Kanig and Edward M. Rudnic. April 1984, p. 50.
Novel erodible polymers for the delivery of macromolecules. R.W. Baker, M.E. Tuttle, and R. Helwing. Feb. 1984, p. 26.
Recent advances in sustained-release technology using ion-exchange polymers. L.P. Amsel, O.N. Hinsvark, K. Rotenberg, and J.L. Sheumaker. April 1984, p. 28.

COST CONTAINMENT

The cost of GLP compliance. H. Fleischhauer. Jan. 1984, p. 26.

CRYSTAL MODIFICATION

Modification of the crystalline structure of sorbitol and its effects on tableting characteristics. James W. DuRoss. Sept. 1984, p. 42.
Modification of the sucrose crystal structure to enhance pharmaceutical properties of excipient and drug substances. A.B. Rizzuto, A.C. Chen, and M.F. Veiga. Sept. 1984, p. 32.

DIRECT COMPRESSION (see COMPRESSION)

DISINTEGRANTS

The mechanisms of disintegrant action. Joseph L. Kanig and Edward M. Rudnic. April 1984, p. 50.

DISSOLUTION

Automated dissolution testing of indomethacin capsules and tablets. C.D. Herzfeldt. Sept. 1984, p. 70.
Guidelines for dissolution testing: an addendum. Don C. Cox, William B. Furman, Terry W. Moore, and Clyde E. Wells. Feb. 1984, p. 42.

DRUG DELIVERY SYSTEMS (see also CONTROLLED RELEASE)

Biodegradable controlled-release parenteral systems. T.R. Tice and D.R. Cowsar. Nov. 1984, p. 26.
Drug delivery systems: a survey of current research settings. Barbara B. Hubert. Aug. 1984, p. 32.
Novel erodible polymers for the delivery of macromolecules. R.W. Baker, M.E. Tuttle, and R. Helwing. Feb. 1984, p. 26.
Ophthalmic drug delivery. Thomas J. Mikkelson. Sept. 1984, p. 90.
Recent advances in sustained-release technology using ion-exchange polymers. L.P. Amsel, O.N. Hinsvark, K. Rotenberg, and J.L. Sheumaker. April 1984, p. 28.

DRUG MARKETS AND MARKETING (see also ADVERTISING)

"On being ethical," in Washington report. James Dickinson. Feb. 1984, p. 22.
"Pharmaceutical megatrends," in Washington report. James Dickinson. Jan. 1984, p. 21.

EDUCATION (see PATIENT EDUCATION)

ELECTROPHORESIS

Protein purification: past, present, and future. Alan J. Parcells. Sept. 1984, p. 78.

ENGINEERING

Automation of HVAC and process controls in a new pharmaceutical manufacturing facility. Robert Rosencranz. Aug. 1984, p. 24.
The design, documentation, and construction of pharmaceutical facilities, part I: design. Robert G. Thompson. Feb. 1984, p. 56.
The design, documentation, and construction of pharmaceutical facilities, part II: documentation. Robert G. Thompson. March 1984, p. 72.
The design, documentation, and construction of pharmaceutical facilities, part III: construction. Robert G. Thompson. April 1984, p. 72.
Digital computer control of batch sterilization. F.J. Dodge. June 1984, p. 60.
Modeling a film coating system for computer automation. D.A. Yoakam and R.J. Campbell. Jan. 1984, p. 38.
A new design for pharmaceutical facilities: the Lhoest-Froment concept. W.J.F. Lhoest and P.J.M. Froment. June 1984, p. 28.
Predicting variable refrigeration and steam demands in batch-type bulk pharmaceutical plants, part II: step-wide plant-wide refrigeration and steam demands. Howard Forster and Edward H. Steve. May 1984, p. 24.
Protection of water treatment systems, part III: validation and control. K.G. Chapman, W.C. Alegnani, G.E. Heinze, C.V. Flemming, J. Kochling, D.B. Croll, M.W. Fitch, M. Kladko, W.J. Lehman, D.C. Smith, F.W. Adair, R.L. Amos, R.M. Enzinger, W.R. Frieben, and T.C. Soli. Sept. 1984, p. 54.
Typical scale-up problems and experiences. Emanuel J. Russo. Nov. 1984, p. 46.

EXCIPIENTS

The mechanisms of disintegrant action. Joseph L. Kanig and Edward M. Rudnic. April 1984, p. 50.
Modification of the crystalline structure of sorbitol and its effects on tableting characteristics. James W. DuRoss. Sept. 1984, p. 42.
Modification of the sucrose crystal structure to enhance pharmaceutical properties of excipient and drug substances. A.B. Rizzuto, A.C. Chen, and M.F. Veiga. Sept. 1984, p. 32.
The use of TTC in USP plate count medium for enumerating low levels of bacteria from insoluble materials. M.A. Goshko. Nov. 1984, p. 58.

FACILITIES

Automation of HVAC and process controls in a new pharmaceutical manufacturing facility. Robert Rosencranz. Aug. 1984, p. 24.
The design, documentation, and construction of pharmaceutical facilities, part I: design. Robert G. Thompson. Feb. 1984, p. 56.
The design, documentation, and construction of pharmaceutical facili-

THE FORCE IN CRITICAL CLEANING

• Laboratories • Hospitals • R & D Facilities • Educational Institutions • General Industry • Electronics • Dairy & Food Processing

Modern sciences and industries are discovering aqueous cleaning to be efficient and safe.

ALCONOX detergents clean without noxious fumes or harsh, dangerous acids or solvents. ALCONOX detergents are concentrated, to be diluted for convenience and economy.

ALCONOX detergents remove difficult soils on glass, plastic, metals, rubber, porcelains, and most hard-surface materials, without leaving film or residue.

ALCONOX detergents complement virtually every aqueous cleaning method or system, either manual or machine. ALCONOX detergents: the force in critical cleaning for today's technologies.

ALCOJET® non-ionic powder, low-sudsing formula especially for use in mechanical washers. Extremely effective, also helps lubricate and protect machine parts.

LIQUI-NOX® phosphate-free anionic and non-ionic liquid detergent for manual and ultrasonic cleaning. ALCONOX efficiency in liquid form. Mild pH.

ALCONOX® the original anionic powder detergent for manual and ultrasonic cleaning. Odorless. High sequestering power. Helps decontaminate radioactive surfaces.

DET-O-JET® alkaline liquid detergent and degreaser for tough cleaning chores. For use in mechanical, pressure-injection, and ultrasonic washers.

TERG-A-ZYME® anionic ALCONOX powder plus protease enzyme to effectively remove proteinaceous soils. Ideal as a pre-soak. *Cleans Reverse-Osmosis Installations.*

Available from all leading laboratory supply companies. FREE samples of ALCONOX detergents will prove their superiority—write today.

ALCONOX, INC.

215 Park Avenue South, New York, N.Y. 10003

Circle Reader Service Card No. 29

ties, part II: documentation. Robert G. Thompson. March 1984, p. 72.

The design, documentation, and construction of pharmaceutical facilities, part III: construction. Robert G. Thompson. April 1984, p. 72.

Electronic control systems for fault elimination in printed packaging. Hermann Stupp. Dec. 1984, p. 38.

A new design for pharmaceutical facilites: the Lhoest-Froment concept. W.J.F. Lhoest and P.J.M. Froment. June 1984, p. 28.

Penicillin decontamination procedures for a pharmaceutical manufacturing facility. Fred Hakimipour. June 1984, p. 88.

Predicting variable refrigeration and steam demands in batch-type bulk pharmaceutical plants, part II: step-wide plant-wide refrigeration and steam demands. Howard Forster and Edward H. Steve. May 1984, p. 24.

Protection of water treatment systems, part III: validation and control. K.G. Chapman, W.C. Alegnani, G.E. Heinze, C.V. Flemming, J. Kochling, D.B. Croll, M.W. Fitch, M. Kladko, W.J. Lehman, D.C. Smith, F.W. Adair, R.L. Amos, R.M. Enzinger, W.R. Frieben, and T.C. Soli. Sept. 1984, p. 54.

FOOD AND DRUG ADMINISTRATION

Balancing science and sense. Mark Novitch. Jan. 1984, p. 18.

Bulk drug substances and purity: a regulatory viewpoint. R.J. Wolters. Oct. 1984, p. 35.

Bulk drug substances and purity: an industry viewpoint. Lester Chafetz. Oct. 1984, p. 24.

FDA inspections: the limits of authority. Niles Ross. March 1984, p. 58.

An FDA perspective on bulk pharmaceutical chemicals. Edmund M. Fry. Feb. 1984, p. 48.

FDA's GLP regulations: proposals for change. P.D. Lepore and M.M. Kemp. Jan. 1984, p. 30.

GMP compliance auditing. Robert Y. Cardner. Sept. 1984, p. 114.

An overview of applying process computer systems to sterile operations. D.J. Fraade. May 1984, p. 48.

The practical application of CGMPs to gas and high-performance liquid chromatographic systems. Johnny Guerra. March 1984, p. 81.

Problems in bulk pharmaceutical chemical production: an FDA investigator's view. Dale E. Cooper. June 1984, p. 72.

Regulatory aspects of aseptic processing. Ronald F. Tetzlaff. Nov. 1984, p. 38.

Validation of computerized systems in the control of drug processes: an FDA perspective. Paul J. Motise. March 1984, p. 40.

Washington report. Monthly column. James Dickinson. Jan. 1984–Dec. 1984.

FOOD, DRUG, AND COSMETIC ACT

FDA inspections: the limits of authority. Niles Ross. March 1984, p. 58.

FORMULATION

The characterization of raw materials. Walter G. Chambliss. June 1984, p. 83.

Characterization techniques for the aqueous film coating process. Leo K. Mathur, St. John Forbes, and Mukund Yelvigi. Oct. 1984, p. 42.

An evaluation of aqueous film-forming dispersions for controlled release. F.W. Goodhart, M.R. Harris, K.S. Murthy, and R.U. Nesbitt. April 1984, p. 64.

An intelligent tablet press monitor for formulation development. J.J. Williams and D.M. Stiel. March 1984, p. 26.

Ophthalmic drug delivery. Thomas J. Mikkelson. Sept. 1984, p. 90.

Stability concepts. PMA's Joint QC-PDS Stability Committee. June 1984, p. 42.

GENERIC DRUGS

"Engman era ends," in Washington report. James Dickinson. Nov. 1984, p. 20.

Generic drugs: an idea whose time has come. Robert Shulman. May 1984, p. 16.

"Generic unsophistication," in Washington report. James Dickinson. Aug. 1984, p. 16.

REMOVE SOLIDS AS SMALL AS .1 MICRON
with a 2-stage Star® filter!

Come on now. Be sensible! How much money are you throwing away on cartridge filters for sub-micron filtration? Stop ignoring the basic filtration rule that the plate & frame is most efficient & economical.

We have a customer who was spending $50,000 a year on one sub-micron operation, using cartridges. Then we sent him a divider plate for one of his many Star filters for two-stage operation down to .1 micron.

Now, he's saving over $45,000 a year on just that one operation!



For economy and efficiency there's no substitute for plate & frame Star-filtration.

SEE OUR THOMCATALOG OR SEND FOR CATALOG AND PRICES TODAY!

Star® Systems Since 1904
FILTRATION DIVISION
(FORMERLY STAR TANK & FILTER CORP.)
Timmonsville, South Carolina 29161

800-845-5381
SC: 803-346-3101
TWX: 810-680-2531
(STAR SYS FLR)

You'll thank your lucky stars you bought a Star!

Circle Reader Service Card No. 31

PHARMATEST INSTRUMENTS

The Alternative in the Field for the Mechanical and Physical Testing of Drugs

DISSOLUTION TEST APPARATUS
Manual, or Automated with Spectrophotometer and Computer Interphase.



DISINTEGRATION TEST APPARATUS BP/USP
Digital Timer; 1, 2 or 3 Stations; Manual, or Automated with Recorder.

FRIABILATOR
Single Drum, 25 rpm; 3 or 6 Drums, Digital and Variable Speed.

SITCO Equipment Division
318 Cleveland Ave., Highland Park, NJ 08904
Telephone: (201) 846-6000 Telex: 833-157

Please write or call for complete line.

Circle Reader Service Card No. 32

"Industry asunder," in Washington report. James Dickinson. Sept. 1984, p. 26.

GOOD LABORATORY PRACTICES

The cost of GLP compliance. H. Fleischhauer. Jan. 1984, p. 26.
FDA's GLP regulations: proposals for change. P.D. Lepore and M.M. Kemp. Jan. 1984, p. 30.

GOOD MANUFACTURING PRACTICES

Bulk drug substances and purity: a European viewpoint. C.A. Johnson. Oct. 1984, p. 28.
Bulk drug substances and purity: an industry viewpoint. Lester Chafetz. Oct. 1984, p. 24.
The Chinese connection. L. Stephen Weiss. March 1984, p. 20.
FDA inspections: the limits of authority. Niles Ross. March 1984, p. 58.
An FDA perspective on bulk pharmaceutical chemicals. Edmund M. Fry. Feb. 1984, p. 48.
GMP compliance auditing. Robert Y. Cardner. Sept. 1984, p. 114.
The PAR approach to process validation. K.G. Chapman. Dec. 1984, p. 22.
The practical application of CGMPs to gas and high-performance liquid chromatographic systems. Johnny Guerra. March 1984, p. 81.
Principles of process automation for liquid and solid dosage forms. Mukund Yelvigi. March 1984, p. 47.
Regulatory aspects of aseptic processing. Ronald F. Tetzlaff. Nov. 1984, p. 38.
Validation of computerized systems in the control of drug processes: an FDA perspective. Paul J. Motise. March 1984, p. 40.

GRANULATIONS

Typical scale-up problems and experiences. Emanuel J. Russo. Nov. 1984, p. 46.

HEATING, VENTING, AND AIR CONDITIONING (HVAC)

Automation of HVAC and process controls in a new pharmaceutical manufacturing facility. Robert Rosencranz. Aug. 1984, p. 24.

INFORMATION

The PAR approach to process validation. K.G. Chapman. Dec. 1984, p. 22.

INNOVATION

The future of R&D. Thi D. Dao. June 1984, p. 16.
Generic drugs: an idea whose time has come. Robert Shulman. May 1984, p. 16.
The need for product innovation. Richard H. Reeves-Ellington. Feb. 1984, p. 18.

INSPECTION DEVICES

Electronic control systems for fault elimination in printed packaging. Hermann Stupp. Dec. 1984, p. 38.

INSPECTIONS

FDA inspections: the limits of authority. Niles Ross. March 1984, p. 58.
Regulatory aspects of aseptic processing. Ronald F. Tetzlaff. Nov. 1984, p. 38.

INSTRUMENTATION

Automated dissolution testing of indomethacin capsules and tablets. C.D. Herzfeldt. Sept. 1984, p. 70.
Chromatographic purification of beta-lactam antibiotics. J. Dwyer, C. Findeisen, and W. Skea. Sept. 1984, p. 100.
Electronic control systems for fault elimination in printed packaging. Hermann Stupp. Dec. 1984, p. 38.

New
AB-1,
AUTOMATIC BALANCE FOR WEIGHING TABLETS AND CAPSULES

MOCON'S NEW AB-1 automatically conveys and weighs product, and prints statistics to immediately determine compliance with USP weight variation requirements. Eliminates time consuming manual weighing of individual tablets or capsules, while producing hard copy printout for permanent record.

For more information, call or write:

MOCON
MODERN CONTROLS, INC.
6820 Shingle Creek Parkway
Minneapolis, Minnesota 55430
612-560-2900

Circle Reader Service Card No. 34

INTRODUCING
THE
LAL · 4000
Automated LAL testing system ... using kinetic turbidmetric methodology

- *Reduced labor*
- *High reproducibility*
- *Quantitative results*
- *Complete data reduction*

Currently scheduling regional seminars, or see the system at the following trade shows:

ASM	*March 3-8 1985*	*Las Vegas*
Interphex	*April 1-3 1985*	*New York*

Pyrotell
Benthos *clinical systems*
Edgerton Dr. No. Falmouth, MA. 02556
Tel. (617) 563-5916 Tlx. 820673

Circle Reader Service Card No. 35

Guidelines for dissolution testing: an addendum. Don C. Cox, William B. Furman, Terry W. Moore, and Clyde E. Wells. Feb. 1984, p. 42.
An intelligent tablet press monitor for formulation development. J.J. Williams and D.M. Stiel. March 1984, p. 26.
Modeling of a film coating system for computer automation. D.A. Yoakam and R.J. Campbell. Jan. 1984, p. 38.
The practical application of CGMPs to gas and high-performance liquid chromatographic systems. Johnny Guerra. March 1984, p. 81.

LABELING

Electronic control systems for fault elimination in printed packaging. Hermann Stupp. Dec. 1984, p. 38.
Problems in bulk pharmaceutical chemical production: an FDA investigator's view. Dale E. Cooper. June 1984, p. 72.

LIQUIDS

Principles of process automation for liquid and solid dosage forms. Mukund Yelvigi. March 1984, p. 47.
Typical scale-up problems and experiences. Emanuel J. Russo. Nov. 1984, p. 46.

LOOK-ALIKE DRUGS (see TRADE DRESS)

LUBRICANTS

Typical scale-up problems and experiences. Emanuel J. Russo. Nov. 1984, p. 46.

MICROBIOLOGY

Considerations in selecting antimicrobial agents for parenteral product development. Michael J. Akers. May 1984, p. 36.
Possible confusion between *Enterobacter agglomerans* and *Escherichia coli*. Marc A. Goshko, Wesley O. Pipes, and Robert R. Christian. Feb. 1984, p. 32.
Protection of water treatment systems, part III: validation and control. K.G. Chapman, W.C. Alegnani, G.E. Heinze, C.V. Flemming, J. Kochling, D.B. Croll, M.W. Fitch, M. Kladko, W.J. Lehman, D.C. Smith, F.W. Adair, R.L. Amos, R.M. Enzinger, W.R. Frieben, and T.C. Soli. Sept. 1984, p. 54.
Protein purification: past, present, and future. Alan J. Parcells. Sept. 1984, p. 78.
The use of TTC in USP plate count medium for enumerating low levels of bacteria from insoluble materials. M.A. Goshko. Nov. 1984, p. 58.
The validation of cleaning procedures. S.W. Harder. May 1984, p. 29.

MICROCAPSULES

Biodegradable controlled-release parenteral systems. T.R. Tice and D.R. Cowsar. Nov. 1984, p. 26.

MODELS

Characterization techniques for the aqueous film coating process. Leo K. Mathur, St. John Forbes, and Mukund Yelvigi. Oct. 1984, p. 42.
Modeling of a film coating system for computer automation. D.A. Yoakam and R.J. Campbell. Jan. 1984, p. 38.
Predicting variable refrigeration and steam demands in batch-type bulk pharmaceutical plants, part II: step-wide plant-wide refrigeration and steam demands. Howard Forster and Edward H. Steve. May 1984, p. 24.

NEW DRUG APPLICATIONS (NDAs)

"Engman era ends," in Washington report. James Dickinson. Nov. 1984, p. 20.
"Found: 5150 unapproved drugs," in Washington report. James Dickinson. Oct. 1984, p. 18.
The future of R&D. Thi D. Dao. June 1984, p. 16.

ESPEC Temperature & Humidity Chambers

Quality Environmental Controls for Dependable Quality Control

The components of ESPEC Temperature and Humidity Chambers have all passed our toughest tests. We put quality into our products so you can get quality out. From our Laboratory and Platinous G. Series Temperature and Humidity Chambers, M Series Large Volume Temperature and Humidity Chambers, Walk-in and L Series Environmental Test Chambers to our complete line of Electronic Test Chambers, as well as Vacuum and Heat Treating Ovens, ESPEC products are designed to perform precisely and dependably.

For more information about our products, call or write and ask for our comprehensive Product Guide.

Quality Built for Testing Quality



ESPEC CORP.
A Subsidiary of Tabai Espec Corp.
400 D-1 CORPORATE COURT
S. PLAINFIELD, NJ 07080
201/753-5900

Circle Reader Service Card No. 36

"Industry asunder," in Washington report. James Dickinson. Sept. 1984, p. 26.

OPHTHALMICS

Ophthalmic drug delivery. Thomas J. Mikkelson. Sept. 1984, p. 90.

OTCs

"A third class of drugs," in Washington report. James Dickinson. May 1984, p. 21.
"A third class of drugs," in Washington report. James Dickinson. Aug. 1984, p. 16.

PACKAGING

Electronic control systems for fault elimination in printed packaging. Hermann Stupp. Dec. 1984, p. 38.

PARENTERALS

Biodegradable controlled-release parenteral systems. T.R. Tice and D.R. Cowsar. Nov. 1984, p. 26.
Considerations in selecting antimicrobial perservative agents for parenteral product development. Michael J. Akers. May 1984, p. 36.
An overview of applying process computer systems to sterile operations. D.J. Fraade. May 1984, p. 48.

PATENTS

"Engman era ends," in Washington report. James Dickinson. Nov. 1984, p. 20.
The future of R&D. Thi D. Dao. June 1984, p. 16.
"Industry asunder," in Washington report. James Dickinson. Sept. 1984, p. 26.

PATIENT EDUCATION

America's youth and the image of the pharmaceutical industry. Mark Knowles. Dec. 1984, p. 14.
"Misprinted PILs," in Washington report. James Dickinson. Nov. 1984, p. 20.
"Pharmaceutical megatrends," in Washington report. James Dickinson. Jan. 1984, p. 21.

PATIENT PACKAGE INSERTS (see PATIENT EDUCATION)

PERSONNEL

FDA inspections: the limits of authority. Niles Ross. March 1984, p. 58.
GMP compliance auditing. Robert Y. Cardner. Sept. 1984, p. 114.

PHARMACEUTICAL INDUSTRY

America's youth and the image of the pharmaceutical industry. Mark Knowles. Dec. 1984, p. 14.
Balancing science and sense. Mark Novitch. Jan. 1984, p. 18.
The Chinese connection. L. Stephen Weiss. March 1984, p. 20.
Defending animal use in biomedical research. Joe R. Held. Oct. 1984, p. 16.
Drug delivery systems: a survey of current research settings. Barbara B. Hubert. Aug. 1984, p. 32.
Drug needs of the elderly. George M. Steinberg. Aug. 1984, p. 14.
"Drugs in the elderly," in Washington report. James Dickinson. Feb. 1984, p. 22.
Fueling the biotechnology fire. Thomas Bugbee. April 1984, p. 16.
The future of R&D. Thi D. Dao. June 1984, p. 16.
Generic drugs: an idea whose time has come. Robert Shulman. May 1984, p. 16.
The need for product innovation. Richard H. Reeves-Ellington. Feb. 1984, p. 18.
"Pharmaceutical megatrends," in Washington report. James Dickinson. Jan. 1984, p. 21.

Promises and pitfalls: the realities of automation. R.T. Mullen. Sept. 1984, p. 24.

PHARMACEUTICAL MANUFACTURING ASSOCIATION (PMA)

"Engman era ends," in Washington report. James Dickinson. Nov. 1984, p. 20.

"Industry asunder," in Washington report. James Dickinson. Sept. 1984, p. 26.

PHARMACEUTICAL TECHNOLOGY

Automation of HVAC and process controls in a new pharmaceutical manufacturing facility. Robert Rosencranz. Aug. 1984, p. 24.

Balancing science and sense. Mark Novitch. Jan. 1984, p. 18.

Characterization techniques for the aqueous film coating process. Leo K. Mathur, St. John Forbes, and Mukund Yelvigi. Oct. 1984, p. 42.

Chromatographic purification of beta-lactam antibiotics. J. Dwyer, C. Findeisen, and W. Skea. Sept. 1984, p. 100.

Digital control in the pharmaceutical industry: a supplier's view. Paul Schwind. June 1984, p. 50.

Digital control of batch sterilization. F.J. Dodge. June 1984, p. 60.

Guidelines for dissolution testing: an addendum. Don C. Cox, William B. Furman, Terry W. Moore, and Clyde E. Wells. Feb. 1984, p. 42.

An intelligent tablet press monitor for formulation development. J.J. Williams and D.M. Stiel. March 1984, p. 26.

Modeling of a film coating system for computer automation. D.A. Yoakam and R.J. Campbell. Jan. 1984, p. 38.

Modification of the crystalline structure of sorbitol and its effects on tableting characteristics. James W. DuRoss. Sept. 1984, p. 42.

Modification of the sucrose crystal structure to enhance pharmaceutical properties of excipient and drug substances. A.B. Rizzuto, A.C. Chen, and M.F. Veiga. Sept. 1984, p. 32.

A new design for pharmaceutical facilities: the Lhoest-Froment concept. W.J.F. Lhoest and P.J.M. Froment. June 1984, p. 28.

An overview of applying process computer systems to sterile operations. D.J. Fraade. May 1984, p. 48.

Predicting variable refrigeration and steam demands in batch-type bulk pharmaceutical plants, part II: step-wide plant-wide refrigeration and steam demands. Howard Forster and Edward H. Steve. May 1984, p. 24.

Promises and pitfalls: the realities of automation. R.T. Mullen. Sept. 1984, p. 24.

Protection of water treatment systems, part III: validation and control. K.G. Chapman, W.C. Alegnani, G.E. Heinze, C.V. Flemming, J. Kochling, D.B. Croll, M.W. Fitch, M. Kladko, W.J. Lehman, D.C. Smith, F.W. Adair, R.L. Amos, R.M. Enzinger, W.R. Frieben, and T.C. Soli. Sept. 1984, p. 54.

Protein purification: past, present, and future. Alan J. Parcells. Sept. 1984, p. 78.

Typical scale-up problems and experiences. Emanuel J. Russo. Nov. 1984, p. 46.

POLYMERS

Biodegradable controlled-release parenteral systems. T.R. Tice and D.R. Cowsar. Nov. 1984, p. 26.

Novel erodible polymers for the delivery of macromolecules. R.W. Baker, M.E. Tuttle, and R. Helwing. Feb. 1984, p. 26.

Recent advances in sustained-release technology using ion-exchange polymers. L.P. Amsel, O.N. Hinsvark, K. Rotenberg, and J.L. Sheumaker. April 1984, p. 28.

PRESERVATIVES

Considerations in selecting antimicrobial preservative agents for parenteral product development. Michael J. Akers. May 1984, p. 36.

NATIONWIDE POSITIONS

ALL POSITIONS FEE PAID — PARTIAL LISTING

•QUALITY ASSURANCE/CONTROL
•QUALITY ENGINEERING
•STERILIZATION

DIR, Q.A. sterile products $48-56M
Q.A. mgr parenterals 45-53M
Q.A. mgr compliance 42-48M
Q.A. mgr I.V. solutions 44-50M
Q.A. mgr documentation 42-48M
Q.A. mgr vendor audits 40-46M
Q.A. mgr biologicals 44-49M
Q.A. mgr validation 43-48M
Q.C. mgr analytical chem lab 44-50M
Q.C. mgr sterilization 38-44M
Q.C. mgr physical testing 41-47M
Q.C. mgr microbiology 37-43M
Q.C. mgr tablets 37-43M
Q.C. mgr opthalmics 40-46M
Q.C. mgr clin lab diag 42-48M
Q.C. mgr flexible containers 40-45M
Q.C. supvr parenterals 28-34M
Q.C. supvr stat bkd 30-35M
Q.C. supvr analytical 29-35M
Q.C. supvr inprocess 27-33M
Q.C. engr documentation 30-35M
Q.C. engr biologicals 30-36M
Q.C. engr reliability 32-37M
Q.C. engr statistics bkd 32-38M
Q.C. engr compliance 30-36M
Q.C. engr medical devices 31-37M
Q.C. engr international 32-38M
Q.C. engr specification writer 30-35M
STERILIZATION specialist 32-40M
STERILIZATION mgr pharm co 42-49M
STERILIZATION engr cycle devel 38-43M
STERILIZATION engr validation 40-47M

•REGULATORY AFFAIRS
•CLINICAL RESEARCH

REGL affairs dir $55-65M
REGL affairs mgr submissions 43-50M
REGL affairs mgr parenterals 42-47M
REGL affairs mgr int'l submissions 45-53M
REGL affairs mgr biotechnology 38-43M
REGL affairs documentation 36-42M
REGL affairs attorney 35-42M
REGL affairs opthalmics 36-43M
REGL affairs sterile products 40-45M
CLINICAL rsch dir parenterals 55-65M
CLINICAL rsch mgr phases I-IV 40-48M
CLINICAL rsch int'l registration 42-50M
CLINICAL rsch cardiovascular 34-38M
CLINICAL rsch IDE bkd 35-39M
CLINICAL rsch gastrointestinal 34-38M
CLINICAL rsch opthalmics 36-40M
CLINICAL rsch analgesics 37-41M
CLINICAL rsch medical devices 36-42M

•MANUFACTURING

PLANT mgr parenterals $60-70M
PLANT mgr biologicals 55-65M
DIR mfg sterile products 52-60M
MFG mgr chemicals 47-54M
MFG mgr opthalmics 48-55M
MFG mgr private label 45-50M
MFG mgr sterile solutions 47-52M
MFG mgr lyophilization 45-50M
MFG mgr immunodiagnostics 46-52M
MFG mgr fermentation 48-54M
MFG mgr LVP 45-52M
PRODN supvr sterile products 27-34M
PRODN supvr tablets 26-33M
PRODN supvr packaging 28-34M
PRODN supvr capsules 27-32M
PRODN supvr ointments, creams 25-31M
PRODN supvr parenterals 29-36M
PRODN supvr aseptic filling 26-32M
PRODN supvr bulk pharm 28-35M
PRODN supvr SVP 28-35M

•TECHNICAL

IMMUNOL. monoclonal antibodies .. $33-40M
IMMUNOLOGIST tumor 34-41M
IMMUNOLOGIST cellular 36-42M
IMMUNOPHARMACIST new tech. ... 35-42M
PROTEIN chemist plasma 38-46M
PROTEIN chemist biopolymers 40-48M
PROTEIN chemist fractionation 35-40M
BIOTECHNOLOGY protein chemist .. 37-42M
BIOTECHNOLOGY fermentation 35-40M
BIOTECHNOLOGY therapeutics 36-41M
BIOTECHNOLOGY enzymology 35-40M
ANALYTICAL chem methods devel .. 33-39M
ANALYTICAL chem HPLC 31-37M
BIOCHEMIST liposomes 32-38M
BIOCHEMIST drug metabolism 33-38M
BIOCHEMIST nucleic acid 31-37M
MOLECULAR biol gene expression .. 32-38M
MOLECULAR biol recombinant DNA 30-37M
POLYMER chemist viscous device .. 34-39M
POLYMER chemist synthesis 35-40M

•PHARMACOLOGIST
•PHARMACIST

DIR, drug delivery systems $65-80M
PHARMACOLOGIST mgr rsch & dev .48-56M
PHARMACOLOGIST anti-inflamm ... 34-42M
PHARMACOLOGIST toxicologist 38-44M
PHARMACOLOGIST cardiovascular .37-43M
PHARMACOLOGIST dermatological .38-43M
PHARMACOLOGIST gastrointestinal .36-41M
PHARMACOLOGIST neuro 37-42M
PHARMACOLOGIST opthalmics 39-45M
PHARMACIST liposome 34-40M
PHARMACIST transdermal drug del .. 32-38M
PHARMACIST sterile products 31-36M
PHARMACIST technical service 35-42M
PHARMACIST Ph.D. phys pharm 38-46M
PHARMACIST parenterals 34-40M
FORMULATION (Ph.D.) solid dosage .37-45M
FORMULATION creams & ointments. 33-39M
FORMULATION controlled release ... 35-42M
FORMULATION capsules 32-36M
FORMULATION (Ph.D.) LVP 39-47M
FORMULATION tablets 32-37M
FORMULATION solutions 33-38M
FORMULATION coatings 32-37M
FORMULATION technical service 35-42M
FORMULATION parenterals 33-39M

•ENGINEERING

DIR process engr sterile products .. $60-70M
PROCESS engr mgr adv control sys .. 44-52M
PROCESS engr mgr parenterals 42-50M
PROCESS engr scale up projects 34-40M
PROCESS engr high viscous prod ... 36-42M
PROCESS engr project mgmt 35-40M
PROCESS engr design 36-43M
PROCESS engr sterilization 38-44M
PROCESS engr biotechnology 35-42M
PROCESS engr polymers 37-43M
CHEM engr fermentation 43-48M
CHEM engr parenterals 36-42M
CHEM engr validation 40-46M
CHEM engr pilot plant 35-42M
MFG engr mgr I.V. products 48-55M
MFG engr plastics or rubber 32-38M
MFG engr sterile products 35-43M
MFG engr wound care 34-42M
MFG engr pharm co/med device exp. 35-45M
MACHINE design specialist 33-41M
INDUSTRIAL engr sterile products ... 33-38M
INDUSTRIAL engr cost control 32-37M
PACKAGING engr I.V. products 32-39M
PACKAGING engr plastics 31-36M
FACIL engr validation 37-44M

ATTENTION: ARE YOU RECRUITING?
TOSS US YOUR TOUGHEST OPENINGS. WE'LL MEET THE CHALLENGE!

Our extensive personnel files reflect the widest cross-section of available candidates in the country. Recruitment problems are immediately researched, and only suitable, qualified people are recommended . . . and we do it with **NO FRONT-END RETAINER. Call Leonard Kalvert — 212/242-2277**

All fees and expenses paid by company.

KALVERT
PERSONNEL SERVICE Inc
80 Eighth Avenue, Dept. PT, New York, NY 10011 • 212/242-2277

All our clients are affirmative action employers.

Circle Reader Service Card No. 38

How ARACLEAN garments improve production and profits

Your "clean" garments may be the dirtiest things in your clean room.

Leading to costly batch contamination and loss.

Now ARACLEAN Services, the nationwide leader in clean room garments offers a two part solution:

1. New materials, new processes

ARACLEAN has helped develop new materials, improved garment construction, processing and radiation or EtO sterilization procedures that offer you sterile garments and accessories certified to Class A particulate requirements as defined by ASTM F51-68 (R-79), allowing us to state...

ARACLEAN Ultra-Clean™ garments are cleaner than they need to be.

Cleaner, in fact, than many clean rooms.

ARACLEAN'S Guarantee:
"Properly handled, ARACLEAN sterile, ultra low particulate garments and accessories will not add any contaminants to the Manufacturing process."

2. And ARACLEAN saves you money

Of course uncontaminated product is your most important money saver but you should experience economies in actual garment costs as well. ARACLEAN'S total garment service is much less expensive than purchasing, maintaining and cleaning your own garments and our standards surpass any local laundry or uniform service.

Free Consultation

We'll tell you how to improve the cleanliness of your clean room garments whether you use our service or not. Call today to schedule a presentation and an ARACLEAN Clean Room Audit.

ARA services

ARACLEAN SERVICES, Inc.
312/352-3206

Marketing Headquarters:
One North Beacon Street, P.O. Box 458, LaGrange, IL 60525
Plants and offices Nationwide

© ARACLEAN SERVICES, Inc. 1983

Circle Reader Service Card No. 40

PROCESS CONTROL

Automation of HVAC and process controls in a new pharmaceutical manufacturing facility. Robert Rosencranz. Aug. 1984, p. 24.
Digital computer control of batch sterilization. F.J. Dodge. June 1984, p. 60.
Digital control in the pharmaceutical industry: a supplier's view. Paul Schwind. June 1984, p. 50.
Modeling of a film coating system for computer automation. D.A. Yoakam and R.J. Campbell. Jan. 1984, p. 38.
A new design for pharmaceutical facilities: the Lhoest-Froment concept. W.J.F. Lhoest and P.J.M. Froment. June 1984, p. 28.
An overview of applying process computer systems to sterile operations. D.J. Fraade. May 1984, p. 48.
The PAR approach to process validation. K.G. Chapman. Dec. 1984, p. 22.
Principles of process automation for liquid and solid dosage forms. Mukund Yelvigi. March 1984, p. 47.
Validation of computerized systems in the control of drug processes: an FDA perspective. Paul J. Motise. March 1984, p. 40.

PROCESS DEVELOPMENT

The characterization of raw materials. Walter G. Chambliss. June 1984, p. 83.
Characterization techniques for the aqueous film coating process. Leo K. Mathur, St. John Forbes, and Mukund Yelvigi. Oct. 1984, p. 42.
Chromatographic purification of beta-lactam antibiotics. J. Dwyer, C. Findeisen, and W. Skea. Sept. 1984, p. 100.
An intelligent tablet press monitor for formulation development. J.J. Williams and D.M. Stiel. March 1984, p. 26.
Predicting variable refrigeration and steam demands in batch-type bulk pharmaceutical plants, part II: step-wide plant-wide refrigeration and steam demands. Howard Forster and Edward H. Steve. May 1984, p. 24.
Protein purification: past, present, and future. Alan J. Parcells. Sept. 1984, p. 78.
Stability concepts. PMA's Joint QC-PDS Stability Committee. June 1984, p. 42.
Typical scale-up problems and experiences. Emanuel J. Russo. Nov. 1984, p. 46.
The validation of cleaning procedures. S.W. Harder. May 1984, p. 29.

PROTEINS

Protein purification: past, present, and future. Alan J. Parcells. Sept. 1984, p. 78.

PURIFICATION

Chromatographic purification of beta-lactam antibiotics. J. Dwyer, C. Findeisen, and W. Skea. Sept. 1984, p. 100.
Protein purification: past, present, and future. Alan J. Parcells. Sept. 1984, p. 78.

PURITY

Bulk drug substances and purity: a European viewpoint. C.A. Johnson. Oct. 1984, p. 28.
Bulk drug substances and purity: a regulatory viewpoint. R.J. Wolters. Oct. 1984, p. 35.
Bulk drug substances and purity: an industry viewpoint. Lester Chafetz. Oct. 1984, p. 24.
The use of TTC in USP plate count medium for enumerating low levels of bacteria from insoluble materials. M.A. Goshko. Nov. 1984, p. 58.

QUALITY ASSURANCE AND QUALITY CONTROL

The characterization of raw materials. Walter G. Chambliss. June 1984, p. 83.
The cost of GLP compliance. H. Fleischhauer. Jan. 1984, p. 26.
Digital control in the pharmaceutical industry: a supplier's view. Paul Schwind. June 1984, p. 50.

Electronic control systems for fault elimination in printed packaging. Hermann Stupp. Dec. 1984, p. 38.
GMP compliance auditing. Robert Y. Cardner. Sept. 1984, p. 114.
Guidelines for dissolution testing: an addendum. Don C. Cox, William B. Furman, Terry W. Moore, and Clyde E. Wells. Feb. 1984, p. 42.
The PAR approach to process validation. K.G. Chapman. Dec. 1984, p. 22.
Penicillin decontamination procedures for a pharmaceutical manufacturing facility. Fred Hakimipour. June 1984, p. 88.
Possible confusion between *Enterobacter agglomerans* and *Escherichia coli*. Marc A. Goshko, Wesley O. Pipes, and Robert R. Christian. Feb. 1984, p. 32.
Principles of process automation for liquid and solid dosage forms. Mukund Yelvigi. March 1984, p. 47.
Problems in bulk pharmaceutical chemical production: an FDA investigator's view. Dale E. Cooper. June 1984, p. 72.
Protection of water treatment systems, part III: validation and control. K.G. Chapman, W.C. Alegnani, G.E. Heinze, C.V. Flemming, J. Kochling, D.B. Croll, M.W. Fitch, M. Kladko, W.J. Lehman, D.C. Smith, F.W. Adair, R.L. Amos, R.M. Enzinger, W.R. Frieben, and T.C. Soli. Sept. 1984, p. 54.
Reference thermal exposures and performance of room temperature stability studies. Salvatori A. Fusari and Gordon L. Hostetler. Jan. 1984, p. 48.

REGULATIONS

Bulk drug substances and purity: a European viewpoint. C.A. Johnson. Oct. 1984, p. 28.
Bulk drug substances and purity: a regulatory viewpoint. R.J. Wolters. Oct. 1984, p. 35.
Bulk drug substances and purity: an industry viewpoint. Lester Chafetz. Oct. 1984, p. 24.
The cost of GLP compliance. H. Fleischhauer. Jan. 1984, p. 26.
FDA inspections: the limits of authority. Niles Ross. March 1984, p. 58.
An FDA perspective on bulk pharmaceutical chemicals. Edmund M. Fry. Feb. 1984, p. 48.
FDA's GLP regulations: proposals for change. P.D. Lepore and M.M. Kemp. Jan. 1984, p. 30.
GMP compliance auditing. Robert Y. Cardner. Sept. 1984, p. 114.
An overview of applying process computer systems to sterile operations. D.J. Fraade. May 1984, p. 48.
The practical application of CGMPs to gas and high-performance liquid chromatographic systems. Johnny Guerra. March 1984, p. 81.
Problems in bulk pharmaceutical chemical production: an FDA investigator's view. Dale E. Cooper. June 1984, p. 72.
Regulatory aspects of aseptic processing. Ronald F. Tetzlaff. Nov. 1984, p. 38.
Stability concepts. PMA's Joint QC-PDS Stability Committee. June 1984, p. 42.
Validation of computerized systems in the control of drug processes: an FDA perspective. Paul J. Motise. March 1984, p. 40.
Washington report. Monthly column. James Dickinson. Jan. 1984–Dec. 1984.

RESEARCH AND DEVELOPMENT

Biodegradable controlled-release parenteral systems. T.R. Tice and D.R. Cowsar. Nov. 1984, p. 26.
Characterization techniques for the aqueous film coating process. Leo K. Mathur, St. John Forbes, and Mukund Yelvigi. Oct. 1984, p. 42.
Defending animal use in biomedical research. Joe R. Held. Oct. 1984, p. 16.
Drug delivery systems: a survey of current research settings. Barbara B. Hubert. Aug. 1984, p. 32.
An evaluation of aqueous film-forming dispersions for controlled release. F.W. Goodhart, M.R. Harris, K.S. Murthy, and R.U. Nesbitt. April 1984, p. 64.

The first and last word in contract sterilization

Fifty years ago, Micro-Biotrol patented Ethylene Oxide [E.O.] gas processing for microbiological control. Today, Micro-Biotrol's VACUGAS® treatment is the largest, most reliable E.O. process in the world — with seventeen locations in ten countries. Our state-of-the-art computerized process control centers guarantee accuracy and safety, plus speedy turn-around times. And Micro-Biotrol's technicians and territory managers are experienced professionals; their standards of excellence are as high as your own.

Micro-Biotrol also offers warehouse distribution, storage, and the most complete QA system in the industry.

If you demand economical, high-quality contract sterilization for cosmetics and pharmaceuticals, isn't it time you talked to the leader?

For more information, please call
Ron Ahnell
[312] 325-6999

Let experience lead you into the future.

MICRO-BIOTROL, INC.
7775 QUINCY STREET
WILLOWBROOK, IL 60521
Bound Brook, NJ • Levittown, PA • Chicago, IL
Smyrna, GA • Los Angeles, CA

Circle Reader Service Card No. 42

The future of R&D. Thi D. Dao. June 1984, p. 16.
An intelligent tablet press monitor for formulation development. J.J. Williams and D.M. Stiel. March 1984, p. 26.
The need for product innovation. Richard H. Reeves-Ellington. Feb. 1984, p. 18.
Novel erodible polymers for the delivery of macromolecules. R.W. Baker, M.E. Tuttle, and R. Helwing. Feb. 1984, p. 26.
Recent advances in sustained-release technology using ion-exchange polymers. L.P. Amsel, O.N. Hinsvark, K. Rotenberg, and J.L. Sheumaker. April 1984, p. 28.

ROTARY PRESSES (see COMPRESSION)

Rx-TO-OTC SWITCH (see OTCs)

SORBITOL

Modification of the crystalline structure of sorbitol and its effects on tableting characteristics. James W. DuRoss. Sept. 1984, p. 42.

SPECIAL PUBLICATIONS

Buyers' Guide. July 1984.
Index to *Pharmaceutical Technology*, Vol. 7 (Jan. 1983 to Dec. 1983). Jan. 1984, p. 56.
Pharm Tech Conference '84 abstracts. Aug. 1984, p. 34.
Pharm Tech Conference '84 report. Nov. 1984, p. 62.

STABILITY

Bulk drug substances and purity: an industry viewpoint. Lester Chafetz. Oct. 1984, p. 24.
Considerations in selecting antimicrobial preservative agents for parenteral product development. Michael J. Akers. May 1984, p. 36.
Reference thermal exposures and performance of room temperature stability studies. Salvatori A. Fusari and Gordon L. Hostetler. Jan. 1984, p. 48.
Stability concepts. PMA's Joint QC-PDS Stability Committee. June 1984, p. 42.

STANDARDS

Automated dissolution testing of indomethacin capsules and tablets. C.D. Herzfeldt. Sept. 1984, p. 70.
Bulk drug substances and purity: a European viewpoint. C.A. Johnson. Oct. 1984, p. 28.
Bulk drug substances and purity: a regulatory viewpoint. R.J. Wolters. Oct. 1984, p. 35.
Bulk drug substances and purity: an industry viewpoint. Lester Chafetz. Oct. 1984, p. 24.
The characterization of raw materials. Walter G. Chambliss. June 1984, p. 83.
Considerations in selecting antimicrobial preservative agents for parenteral product development. Michael J. Akers. May 1984, p. 36.
An FDA perspective on bulk pharmaceutical chemicals. Edmund M. Fry. Feb. 1984, p. 48.
Problems in bulk pharmaceutical chemical production: an FDA investigator's view. Dale E. Cooper. June 1984, p. 72.
Stability concepts. PMA's Joint QC-PDS Stability Committee. June 1984, p. 42.

STERILE OPERATIONS

An overview of applying process computer systems to sterile operations. D.J. Fraade. May 1984, p. 48.

NEW
BFM-180 Blister Pack



Finally, here is a blisterpack machine that has everything you've wanted – performance, versatility, reliability, and value in a compact size. Meet the new Betz BFM-180. The BFM-180 has pressure forming and platen sealing with a smooth continuous motion web travel through the form fill seal section. Changeovers are fast and easy. The BFM-180 has many advanced features such as zoned teflon coated heating plates with individual temperature controls, contact cooling after sealing, and automatic and continuous registration of the sealing station to the blister cavity. These features are either options or are not even available on other machines. But, they are standard on the BFM-180. Best of all, the BFM-180 has an affordable price tag that you won't believe!

The BFM-180 is just one of many fine machines available from Garon. Let our product line and expertise solve your packaging problems.

The new BFM-180. The answer to your blisterpack problems.

Garon Machinery Company, Inc.
Salem Industrial Park – Hwy 22
P.O. Box 17
Whitehouse Station, N.J. 08889
Phone (201) 534-2167 Tlx 833703

Circle Reader Service Card No. 44

STOP METALLIC CONTAMINATION

BARKLEY & DEXTER/LOCK

METALCHEK 9X

INSPECT UP TO 10,000 TABLETS PER MINUTE.

Avoid the risk of costly, damaging litigation and the devastating loss of reputation and business. The Metalchek 9X is regarded by many of the world's leading pharmaceutical companies as the standard of the industry for the inspection, detection and automatic rejection of metal contaminated tablets and capsules. Contact us today for complete information on the Metalchek 9X... "The One That Works"



Barkley & Dexter Laboratories, Inc.
50 Frankfort St. P.O. Box 307
Fitchburg, MA 01420
Tel (617) 343-3716
Telex 710-347-6394

Circle Reader Service Card No. 46

PHARMACEUTICAL TECHNOLOGY

REPRINT SERVICE

Enhance the value of information programs through the use of papers published in *Pharmaceutical Technology*.

- Training and educating sales and marketing staff
- Content information for industry seminars and conferences
- Informative literature for product users
- Collateral material for classroom text

Volume orders (minimum of 250 copies) of all previous and future articles in *Pharmaceutical Technology* are available exclusively through:

PUBLISHERS DATA CORPORATION

320 N. A St.
P.O. Box 50
Springfield, OR 97477
(503) 726-1211

Circle Reader Service Card No. 47

Problems in bulk pharmaceutical chemical production: an FDA investigator's view. Dale E. Cooper. June 1984, p. 72.
Regulatory aspects of aseptic processing. Ronald F. Tetzlaff. Nov. 1984, p. 38.

STERILIZATION (see also CONTAMINATION)

Considerations in selecting antimicrobial preservative agents for parenteral product development. Michael J. Akers. May 1984, p. 36.
Digital computer control of batch sterilization. F.J. Dodge. June 1984, p. 60.
Protection of water treatment systems, part III: validation and control. K.G. Chapman, W.C. Alegnani, G.E. Heinze, C.V. Flemming, J. Kochling, D.B. Croll, M.W. Fitch, M. Kladko, W.J. Lehman, D.C. Smith, F.W. Adair, R.L. Amos, R.M. Enzinger, W.R. Frieben, and T.C. Soli. Sept. 1984, p. 54.
Regulatory aspects of aseptic processing. Ronald F. Tetzlaff. Nov. 1984, p. 38.

SUCROSE

Modification of the sucrose crystal structure to enhance pharmaceutical properties of excipient and drug substances. A.B. Rizzuto, A.C. Chen, and M.F. Veiga. Sept. 1984, p. 32.

SUPPOSITORIES

Typical scale-up problems and experiences. Emanuel J. Russo. Nov. 1984, p. 46.

TABLETS AND TABLETING

Automated dissolution testing of indomethacin capsules and tablets. C.D. Herzfeldt. Sept. 1984, p. 70.
Characterization techniques for the aqueous film coating process. Leo K. Mathur, St. John Forbes, and Mukund Yelvigi. Oct. 1984, p. 42.
Guidelines for dissolution testing: an addendum. Don C. Cox, William B. Furman, Terry W. Moore, and Clyde E. Wells. Feb. 1984, p. 42.
An intelligent tablet press monitor for formulation development. J.J. Williams and D.M. Stiel. March 1984, p. 26.
The mechanisms of disintegrant action. Joseph L. Kanig and Edward M. Rudnic. April 1984, p. 50.
Modeling of a film coating system for computer automation. D.A. Yoakam and R.J. Campbell. Jan. 1984, p. 38.
Modification of the crystalline structure of sorbitol and its effects on tableting characteristics. James W. DuRoss. Sept. 1984, p. 42.
Modification of the sucrose crystal structure to enhance pharmaceutical properties of excipient and drug substances. A.B. Rizzuto, A.C. Chen, and M.F. Veiga. Sept. 1984, p. 32.
Principles of process automation for liquid and solid dosage forms. Mukund Yelvigi. March 1984, p. 47.

TEMPERATURE

Reference thermal exposures and performance of room temperature stability studies. Salvatori A. Fusari and Gordon L. Hostetler. Jan. 1984, p. 48.

TESTING

Automated dissolution testing of indomethacin capsules and tablets. C.D. Herzfeldt. Sept. 1984, p. 70.
Considerations in selecting antimicrobial preservative agents for parenteral product development. Michael J. Akers. May 1984, p. 36.
Guidelines for dissolution testing: an addendum. Don C. Cox, William B. Furman, Terry W. Moore, and Clyde E. Wells. Feb. 1984, p. 42.
Penicillin decontamination procedures for a pharmaceutical manufacturing facility. Fred Hakimipour. June 1984, p. 88.
Possible confusion between *Enterobacter agglomerans* and *Escherichia coli*. Marc A. Goshko, Wesley O. Pipes, and Robert R. Christian. Feb. 1984, p. 32.
Problems in bulk pharmaceutical chemical production: an FDA investigator's view. Dale E. Cooper. June 1984, p. 72.

UNIVERSAL PROCESS EQUIPMENT COMPANY purchases complete pharmaceutical manufacturing plants, discontinued pharmaceutical production lines or individual pieces of pharmaceutical type equipment.

CALL OUR BUYING DEPARTMENT NOW!

Universal Process Equipment, Inc.
P.O. Box 338PT
Roosevelt, New Jersey 08555
Telephone: (609) 443-4545
Telex 833021
Plant site: Rte. 130 South
Robbinsville, New Jersey 08691

Circle Reader Service Card No. 49

LYOPHILIZATION SEMINAR

KEY WEST, FLORIDA
APRIL 2, 3, & 4, 1985

Learn how to:
Perform Thermal Analysis
Develop an Optimum Freeze Drying Cycle
Determine Dryer Specifications

Fees of $685.00 per person ($600.00 @ for three or more) includes bound seminar notes, luncheons and coffee breaks.

Seminar is limited to the first 15 to register.

For your free brochure and application form, call 215-667-2896 or write:

T.A. Jennings Associates, Inc.
P.O. Box 527
Bala Cynwyd, PA 19004

Reference thermal exposures and performance of room temperature stability studies. Salvatori A. Fusari and Gordon L. Hostetler. Jan. 1984, p. 48.
Stability concepts. PMA's Joint QC-PDS Stability Committee. June 1984, p. 42.
The use of TTC in USP plate count medium for enumerating low levels of bacteria from insoluble materials. M.A. Goshko. Nov. 1984, p. 58.
The validation of cleaning procedures. S.W. Harder. May 1984, p. 29.

TRADE DRESS

A fresh look at new dosage forms. Edward S. Brady. Aug. 1984, p. 22.

TRAINING

GMP compliance auditing. Robert Y. Cardner. Sept. 1984, p. 114.

UNITED STATES PHARMACOPEIA

Automated dissolution testing of indomethacin capsules and tablets. C.D. Herzfeldt. Sept. 1984, p. 70.
Bulk drug substances and purity: a European viewpoint. C.A. Johnson. Oct. 1984, p. 28.
Bulk drug substances and purity: an industry viewpoint. Lester Chafetz. Oct. 1984, p. 24.
Guidelines for dissolution testing: an addendum. Don C. Cox, William B. Furman, Terry W. Moore, and Clyde E. Wells. Feb. 1984, p. 42.
Possible confusion between *Enterobacter agglomerans* and *Escherichia coli*. Marc A. Goshko, Wesley O. Pipes, and Robert R. Christian. Feb. 1984, p. 32.
The use of TTC in USP plate count medium for enumerating low levels of bacteria from insoluble materials. M.A. Goshko. Nov. 1984, p. 58.

USER FEES

"FDA user fees," in Washington report. James Dickinson. April 1984, p. 20.

VALIDATION

The characterization of raw materials. Walter G. Chambliss. June 1984, p. 83.
An overview of applying process computer systems to sterile operations. D.J. Fraade. May 1984, p. 48.
The PAR approach to process validation. K.G. Chapman. Dec. 1984, p. 22.
Principles of process automation for liquid and solid dosage forms. Mukund Yelvigi. March 1984, p. 47.
Protection of water treatment systems, part III: validation and control. K.G. Chapman, W.C. Alegnani, G.E. Heinze, C.V. Flemming, J. Kochling, D.B. Croll, M.W. Fitch, M. Kladko, W.J. Lehman, D.C. Smith, F.W. Adair, R.L. Amos, R.M. Enzinger, W.R. Frieben, and T.C. Soli. Sept. 1984, p. 54.
Regulatory aspects of aseptic processing. Ronald F. Tetzlaff. Nov. 1984, p. 38.
The validation of cleaning procedures. S.W. Harder. May 1984, p. 29.
Validation of computerized systems in the control of drug processes: an FDA perspective. Paul J. Motise. March 1984, p. 40.

WATER

Protection of water treatment systems, part III: validation and control. K.G. Chapman, W.C. Alegnani, G.E. Heinze, C.V. Flemming, J. Kochling, D.B. Croll, M.W. Fitch, M. Kladko, W.J. Lehman, D.C. Smith, F.W. Adair, R.L. Amos, R.M. Enzinger, W.R. Frieben, and T.C. Soli. Sept. 1984, p. 54.

YOUNG, FRANK E.

"FDA is changing, too," in Washington report. James Dickinson. Nov. 1984, p. 20.